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Endonexin (protein II, 32.5 kDa) has been purified to homogeneity from bovine liver in the following steps: 
selective xtraction by EGTA from membranes precipitated with T&on X-lOO/calcium; chromatography 
on DEAE-TSK 545 at pH 7.0, endonexin being eluted at 0.1 M NaCl; affinity chromatography on polyacryl- 
amide-immobilized phosphatidylserine; gel filtration on TSK 3000. The amino acid composition was essen- 
tially similar to that previously reported. Using PH]oleic acid-lahelled Escherichia coli membranes as sub- 
strate, endonexin inhibited phospholipase 4 from pig pancreas. Maximal inhibition was 55 and 70%, where- 
as 50% inhibition occurred at 480 and 120 nM endonexin and lipocortin II, respectively. These data could 
be related to common features shared by both lipocortins/calpactins and endonexin, i.e. the presence of a 
consensus equence and the ability to bind to anionic phospholipids in a calcium-dependent manner. 
Endonexin; Lipocortin; Phospholipase 4; Ca2+; Phosphatidylserine 
1. INTRODUCTION 
Lipocortins (LCs) have been described as a 
group of proteins exerting anti-inflammatory ef- 
fects through an inhibitory effect against PLA2 
[l-6] (see also [7-91 for reviews and 
nomenclature). Considerable progress was recently 
made in this field by immunological approaches 
[lo-131, but mainly by obtaining sequence infor- 
mation from either purified LC preparations 
[14,15] or the corresponding cDNA [16,17]. These 
studies revealed two striking features: (i) two types 
of LC exist (I and II), present in a monomeric or 
tetrameric form, and identical to calpactins II and 
I, respectively [17-191. Both proteins display a 
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50% sequence homology of the 35-36 kDa chain 
and LC II (protein I or ~36) was recently described 
as an inhibitor of PLA2 [20]. (ii) A 17 amino acid 
residue consensus equence has been identified not 
only in LCs, but also in a group of other proteins, 
including 34 and 67 kDa calelectrins as well as en- 
donexin, a 32.5 kDa protein isolated from bovine 
adrenal gland and liver ([21-241; recent reviews 
[25,26]). Finally, some sequence homology was 
also noticed between LC and ras gene proteins 
~271. 
Although all of these proteins behave as 
calcium- and phospholipid-dependent membrane- 
binding proteins, their physiological significance 
still remains obscure. Fragmentary data ac- 
cumulated so far concern anti-PLA2 activity of 
LCs [l-6,14,17,20], their phosphorylation by 
tyrosine kinases [ 12,13,15,28] or serine/threonine 
protein kinases [29-321, related to some possible 
regulation of anti-PLA2 activity [28-321. There are 
also some reports on the enhancement of secretory 
granule aggregation by calelectrins or endonexin 
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[33] and on the subcellular localization of these 
proteins [34-381. 
One of the questions raised by this information 
is whether this anti-PLAz activity is specific for 
LCs or is also shared by other related proteins like 
calelectrins or endonexin. The present study pro- 
vides evidence for an anti-PLAz activity of en- 
donexin. 
2. MATERIALS AND METHODS 
[3H]Oleic acid (8.9 Ci/mmol) was from NEN 
(Dreieich). Phosphatidylserine (bovine brain), fat- 
ty acid-free BSA and PLAz (pig pancreas, 
900 U/mg) were from Sigma (St. Louis, MO). 
2.1. Purification of endonexin 
An EGTA extract was prepared from bovine 
liver as in [37]. After overnight dialysis against 
buffer A (10 mM Hepes, pH 7.4, 0.5 mM 
FRACTION NUMBER 
Fig. 1. Affinity chromatography of salt gradient DEAE- 
TSK fractions on polyacrylamide-immobilized phos- 
phatidylserine. After washing the column with buffer A 
containing 100 mM NaCl and 1 mM CaC12, proteins 
retained on the column were eluted as shown at the 
arrow by the same buffer containing 5 mM EGTA 
instead of CaCl2 (flow rate 15 ml/h; fraction volume 
3 ml). Inset: SDS-polyacrylamide gel electrophoresis of 
various fractions detected by silver staining. Lanes: a, 
EGTA extract; b, protein pool after salt gradient on 
DEAE-TSK column; c,d, fraction numbers 5 and 10 
non-retained on polyacrylamide-immobilized phos- 
phatidylserine; e-g: fraction nos 18-20 eluted with 
5 mM EGTA. 
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Fig.2. Elution profile of protein from TSK gel G3000 
SW column chromatography (flow rate 2 ml/min, 
fraction volume 2 ml). Inset: SDS-polyacrylamide gel 
electrophoresis of fractions detected by silver staining. 
dithiothreitol, 1 mM NaN3) and clarification by 
centrifugation (100000 x g, 60 min, 4”C), the ex- 
tract was loaded onto a column of DEAE-TSK 545 
(21.5 x 150 mm) equilibrated with buffer A. The 
Table 1 
Amino acid composition of 32.5 kDa protein 
Amino acid mol%” molt70b 
Asx 10.2 11.4 
Thr 4.6 5.7 
Ser 9.8 6.4 
Glx 11.7 13.6 
Pro 2.3 1.8 
GlY 10.5 7.9 
Ala 8.9 8.6 
Val 3.7 3.9 
Met 2.0 2.1 
Ile 5.9 5.7 
Leu 8.6 10.7 
Tyr 2.7 3.2 
Phe 3.1 3.6 
His 2.3 1.4 
Lys 7.7 7.1 
Arg 6.1 5.4 
CYS ND 1.4 
a Values are expressed as mol% and are extrapolated to 
zero time from two analyses performed after 20 and 
70 h hydrolysis 
b From Sudhof et al. [33] 
ND, not determined 
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flow-through fractions were discarded and the col- 
umn was developed with a O-O.3 M NaCl gradient. 
Fractions containing endonexin eluted at around 
0.1 M NaCl. They were pooled and loaded onto a 
polyacrylamide-immobilized phosphatidylserine 
column prepared as in [39] and equilibrated with 
buffer A containing 100 mM KC1 and 1 mM 
CaC12. The major part of the proteins was not re- 
tained by the column, except for a small peak 
eluted by replacing CaC12 by 5 mM EGTA. The 
purified fractions were further submitted to gel 
filtration on a column of TSK 3000 (21.5 x 
600 mm) equilibrated with buffer A containing 
100 mM KCI. Protein purity was checked at the 
various steps of the procedure by SDS- 
polyacrylamide gel electrophoresis [40], proteins 
being detected by silver staining, using a kit from 
Biorad (Richmond, CA). 
2.2. Purification of lipocortin 
LC II (calpactin I, 85 kDa) was isolated from 






step. SDS-polyacrylamide gel electrophoresis 
revealed the presence of two bands at 37 and 
10 kDa, corresponding to heavy and light chain of 
the tetramer, respectively, together with two pro- 
teolytic fragments at 33 and 22 kDa. 
2.3. Determination of PLA2 activity 
This was performed as in [41] using [3H]oleic 
acid-labelled Escherichia coli membranes isolated 
after autoclaving [42], with the following 
modifications: endonexin or LC was preincubated 
with PLA2 (200 ng) at 4°C for 10 min, followed by 
addition of E. coli membranes and further incuba- 
tion at 4°C for 20 min. Radioactivity of released 
[3H]oleic acid was determined as in [41]. 
2.4. Miscellaneous 
Protein was determined as in [43]. Amino acid 
hydrolysis of endonexin was performed at 110°C 
under vacuum in 6 M HCI for 20 or 70 h. 
Hydrolysates were analysed using a Beckman 6300 
analyzer. 
Fig.3. Effect of endonexin (x), lipocortin II ( q ) and bovine serum albumin (+) on phospholipase A2 activity. Aliquots 
of different proteins were incubated with 200 ng pig pancreas phospholipase AZ and activities were detected as described 
in section 2. Results are given as means from two determinations and are expressed as percentage of the phospholipase 
A2 activity measured without proteins (100%). 
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3. RESULTS 
The inset to fig.1 illustrates the various steps 
used for endonexin purification. The EGTA ex- 
tract from pig liver contained a large number of 
proteins (lane a), which was hardly decreased after 
chromatography on DEAE-TSK 545 (lane b). 
Upon loading onto a column of polyacrylamide- 
immobilized phosphatidylserine quilibrated with 
a buffer containing 1 mM CaC12, most of these 
proteins were recovered in the flow-through frac- 
tions (fig.1 and lanes c,d). This allowed a high 
degree of purification of the proteins retained on 
the column and eluted with EGTA. As shown in 
lanes e-g, the last fraction of the small peak was 
particularly enriched in two proteins (67 and 
32.5 kDa), together with a 24 kDa fragment. 
Based on its molecular mass, its ability to bind to 
DEAE-TSK 545 at pH 7.0 and its calcium- 
dependent phospholipid-binding property, the 
32.5 kDa protein was identified as endonexin 
[32,38]. 






TSK 3000. As shown in fig.2, no clear separation 
between the various proteins could be achieved, 
since the main peak at fraction 42 still contained 
both 67 and 32.5 kDa proteins, with some traces of 
the 24 kDa fragment. However, starting from 
fraction 46 until fraction 52, corresponding to the 
total volume of the column, endonexin was obtain- 
ed in pure form, as revealed by polyacrylamide gel 
electrophoresis (fig.2, inset). These data indicate 
that some aggregation between the three proteins 
probably occurred, as well as some interaction 
with the TSK matrix. Fractions 48-52 were pooled 
and, again, it was verified that endonexin appeared 
as a single band upon SDS-polyacrylamide gel elec- 
trophoresis (not shown). 
The amino acid analysis of purified endonexin is 
given in table 1. Our data are rather comparable to 
those of Stidhoff et al. [33]. Two preliminary at- 
tempts to sequence endonexin remained unsuc- 
cessful, suggesting that the N-terminal end of the 
protein could be blocked. At present, no sequence 
data on endonexin N-terminal end are available in 
the literature. 
Fig.4. Dose-response curve of the inhibition of phospholipase A2 activity by endonexin (x) and lipocortin II (0). 
Conditions as in fig.3, except hat 50 pg bovine serum albumin was added to the incubation medium. Results are given 
as means k SE from three experiments. 
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Upon incubation in the presence of pig pancreas 
PLA2, endonexin promoted a dose-dependent 
decrease in enzyme activity very similar to that in- 
duced by LC (fig.3). In order to exclude any non- 
specific action of these proteins, their effects were 
compared to those of BSA. As also shown in fig.3, 
BSA actually stimulated PLAz activity about 
5-fold. Further experiments were therefore per- 
formed in the presence of a BSA concentration 
(2.1 PM) allowing maximal PLA2 activity. As 
shown in fig.4, both endonexin and LC still ex- 
erted the same inhibitory action against PLA2. En- 
donexin appeared somewhat less active than LC, 
PLA2 maximal inhibition being 55 and 70%, 
respectively. Moreover, 50% inhibition of PLA2 
was obtained at 120 and 480 nM LC and endonex- 
in, respectively, taking 85 and 32.5 kDa as the cor- 
responding molecular masses. In comparison, 
Khanna et al. [20] found half-maximal inhibition 
of PLA;! by 223 nM LC II, vs 72 nM for LC I 
(37 kDa), as reported by Pepinsky et al. [14]. 
4. DISCUSSION 
Our data present clear evidence that endonexin 
displays an anti-PLA2 activity similar to that of 
LCs. Although the amino acid composition does 
not represent a definitive characterization of en- 
donexin, the protein used here could be differen- 
tiated from LCs on the basis of a different charge 
(LCs are not retained by DEAE ion exchangers at 
pH 7.0) and a different molecular mass: 32.5 kDa 
for endonexin, vs 35-37 kDa for LC I or heavy 
chain of LC II [11,14,15,17,32,37,38]. Moreover, 
there is no risk that the protein purified herein 
could be a proteolytic cleavage product of LC, for 
instance, core protein, 33 kDa, from LC II or 
calpactin I, since the latter should also be detected 
in the flow-through fractions of DEAE-TSK 
chromatography [44]. Furthermore, liver has been 
shown to lack or to contain barely detectable 
amounts of LCs or their corresponding mRNA 
[11,14,16]. 
The anti-PLA2 activity described here is rather 
specific since BSA, chosen as a negative control, 
actually stimulated PLA2 activity. This might be 
due to the removal from the lipid interface of fatty 
acids produced by PLA2. It should also be recalled 
that Khanna et al. [20] checked various calcium- 
binding proteins such as parvalbumin or 
calmodulin and did not find any anti-PLA2 activi- 
ty, except for LC II (also called p36 or protein I). 
Our present finding is important to consider in 
the light of the known similarities between 
LCs/calpactins reported above, as well as the abili- 
ty of these proteins to adsorb onto phospholipid 
surfaces in a calcium-dependent manner. It is thus 
tempting to suggest that the anti-PLAz activity 
described in vitro either involves a specific interac- 
tion between PLA2 and these various proteins 
(possibly through the homologous part present in 
each of them), or is subsequent o some kind of 
steric hindrance occurring at the lipid/water inter- 
face, owing to the calcium-mediated adsorption of 
endonexin or LC. In this respect, it is worth recall- 
ing that E. coli membranes have a relatively high 
content of anionic phospholipids such as 
phosphatidylglycerol or cardiolipin [45], which are 
those favoring calcium-dependent interfacial ad: 
sorption of LC or endonexin. 
Whatever be the molecular mechanism of the 
anti-PLA2 action of endonexin, our observation 
raises some very intriguing questions concerning 
the biological significance of these various pro- 
teins. Since the first reports of glucocorticoid- 
induced protein inhibitors of PLA2 [l-6], there is 
now evidence for the presence in various tissues, 
even in the absence of any glucocorticoid treat- 
ment, of at least three different proteins (LCs I and 
II, endonexin) displaying a similar in vitro anti- 
PLAz activity. Whether this reflects some reality of 
the in vivo situation still remains an open question 
and should warrant further studies. 
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